Fig. 7: Candidate compounds potentiate the effect of cytarabine in AML 8227.
From: Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia
a Viability of bulk, CD15+ (mature blast) and CD34+ CD38− AML 8227 cells treated with cytarabine at indicated concentrations for 6 days. b–d Viability of b bulk, c CD15+ and d CD34+ CD38− AML 8227 treated with cytarabine in combination with either DMSO, 10 µM astemizole, 30 nM strophanthidin or 10 nM mometasone for 6 days. Data are representative of three independent experiments performed in triplicate and represent the mean ± s.d.
